MSCs can reduce mortality, clinical symptom improvement time, and days to hospital discharge, with mild adverse effects, improve clinical symptoms, and decrease inflammatory cytokines CRP levels in patients with COVID‐19. This evidence concerns the gene CRP and COVID-19.